Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Change in Cash (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Change in Cash for 7 consecutive years, with $244.1 million as the latest value for Q4 2025.

  • Quarterly Change in Cash rose 2456.02% to $244.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $236.8 million through Dec 2025, up 2204.69% year-over-year, with the annual reading at $236.8 million for FY2025, 2204.69% up from the prior year.
  • Change in Cash for Q4 2025 was $244.1 million at Kymera Therapeutics, up from -$222.9 million in the prior quarter.
  • The five-year high for Change in Cash was $245.9 million in Q2 2025, with the low at -$222.9 million in Q3 2025.
  • Average Change in Cash over 5 years is $16.5 million, with a median of $15.8 million recorded in 2021.
  • The sharpest move saw Change in Cash plummeted 1470.87% in 2024, then surged 2456.02% in 2025.
  • Over 5 years, Change in Cash stood at -$104.3 million in 2021, then increased by 16.36% to -$87.2 million in 2022, then surged by 133.16% to $28.9 million in 2023, then plummeted by 66.99% to $9.5 million in 2024, then soared by 2456.02% to $244.1 million in 2025.
  • According to Business Quant data, Change in Cash over the past three periods came in at $244.1 million, -$222.9 million, and $245.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.